Eris Lifesciences Q3 Results Review - Inline Quarter; New Launches Scale-Up Is Key: Prabhudas Lilladher

Prabhudas Lilladher Report

Eris Lifesciences Ltd. reported muted performance during the quarter, due to higher promotional expenses from new launches. However, we maintain our estimates and continue to believe benefits of operating leverage will play out, as revenue scales up from these new launches.

Acquisition of Oaknet and Glenmark Pharmaceuticals’s derma portfolio to strengthen Eris’s entry in the derma segment, which is currently operating at sub optimal profitability. Eris’s turnaround of Strides Pharma Science Ltd. acquired portfolio provides comfort for similar executions.

Eris continues to outperform core cardio metabolic market which expects robust growth over next three years with wide patent expiration opportunities.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.